The third among the 10 stocks insiders are getting rid of in March is a commercial-stage biotech, Adaptive Biotechnologies ...

Recently, the company announced it has launched an upgraded version of its clonoSEQ assay for measurable residual disease (MRD) detection in diffuse large B-cell lymphoma (DLBCL) using circulating ...

for patients with DLBCL clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ...

Success in the first-line DLBCL setting with MRD-positive patients would validate the company’s approach and potentially position cema-cel as a frontline therapy option. This could lead to a ...

in first-line diffuse large B-cell lymphoma (DLBCL) patients with minimal residual disease (MRD). This trial is particularly significant as it targets patients with lower disease burden, a setting ...

Goldman Sachs analyst Salveen Richter upgraded Adaptive Biotechnologies (ADPT) to Buy from Neutral with a $9 price target Since October 2024, ...

June 20, 2024 — Research scientists found that a 'one-two punch' of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to ...